JYMed e fuoe tokelo ea molao ea Europe bakeng sa mokhoa oa eona o mocha oa ho kopanya Liraglutide. Ketsahalo ena ea bohlokoa e totobatsa boetapele ba rona bo tsoelang pele ho peptide R&D le IP. Patent ena e emela ts'ebetso e ncha ea ho kopanya liraglutide, e sa tiiseng feela chai e tsitsitseng empa hape e fokotsa haholo ho thehoa ha litšila tsa morabe [D-Thr ^ 5] -Liraglutide, e batlang e tšoana hantle le sehlahisoa se lebisitsoeng. Tlhahiso ena e ntlafatsa boleng ba sehlahisoa ka kakaretso.

Ho nkuoa ha tokelo ea molao ea Europe ho bonts'a bokhoni bo felletseng ba R&D ba k'hamphani, ho tiisa le ho feta melemo ea eona ea thekenoloji. E thusa ho matlafatsa tlholisano ea mantlha ea JYMed le ho holisa boteng ba eona mebarakeng ea machabeng. Ho feta moo, e matlafatsa melemo ea thepa ea bohlale ea k'hamphani, e thusa ho boloka le ho ntlafatsa tlholisano ea eona ea 'maraka oa lefats'e.

Hubei JXBio Pharmaceutical Co., Ltd, e leng lekala la Shenzhen JYMed Technology Co., Ltd, e sa tsoa amohela Tsebiso ea Kamohelo ea 'Maraka bakeng sa Oxytocin Active Pharmaceutical Ingredient (API) e fanoeng ke Tsamaiso ea Naha ea Lihlahisoa tsa Bongaka (NMPA) ea Chaena.

Tumello ena e bolela hore JXBio's oxytocin API e kopana le litlhoko tsa tekheniki tsa taolo tse behiloeng ke tsamaiso ea naha ea tlhahlobo ea lithethefatsi. E tšoaea ketsahalo ea bohlokoa bakeng sa k'hamphani, e ntlafatsa ho feta potefolio ea lihlahisoa tsa eona le ho fana ka motheo o tiileng oa katoloso ea 'maraka lekaleng la oxytocin.
MABAKA JYMED
JYMed ke k'hamphani ea theknoloji e phahameng ea biopharmaceutical e sebetsanang le lipatlisiso tse ikemetseng, nts'etsopele, tlhahiso, le thekiso ea lihlahisoa tse thehiloeng ho peptide, hammoho le lits'ebeletso tsa nts'etsopele ea konteraka le mokhatlo oa tlhahiso (CDMO). Khamphani e ikemiselitse ho fana ka li-API tsa boleng bo holimo tsa peptide le litharollo tse ikhethileng ho bareki ba lefats'e. Sehlahisoa sa eona sa lihlahisoa se kenyelletsa li-API tse ngata tsa peptide, tse nang le lihlahisoa tsa mantlha tse kang Semaglutide le Terlipressin tse seng li qetile ho tlatsa US FDA DMF.

Katlase ea eona, Hubei JXBio Pharmaceutical Co., Ltd., e sebetsa mekhoa ea tlhahiso ea peptide ea morao-rao ea API e lumellanang le litekanyetso tsa cGMP tse behiloeng ke US FDA, European EMA, le NMPA ea Chaena. Setsi sena se kenyelletsa mela e 10 e meholo le ea liteko tsa tlhahiso mme e thehile sistimi e thata ea taolo ea boleng ba meriana (QMS) le sistimi ea taolo ea bophelo bo botle le polokeho ea tikoloho (EHS). Tsena li netefatsa hore ts'ebetso eohle, ho tloha ho R&D ho isa tlhahisong, e kopana le litekanyetso tse phahameng ka ho fetisisa tsa machaba. Khamphani e atlehile ho feta tlhahlobo ea melao ea GMP ke US FDA le NMPA ea China 'me e amohetsoe ke lik'hamphani tse etelletseng pele tsa meriana lefatšeng ka bophara bakeng sa bokhabane ba eona ba taolo ea EHS, e bonts'a boitlamo ba eona bo ikhethang ba boleng, polokeho le boikarabello ba tikoloho.

Libaka tse kholo tsa Khoebo:Ngoliso ea API ea lapeng le ea machabeng le ho latela melao ea eona,Li-peptide tsa bongaka ba liphoofolo le litlolo,Litšebeletso tsa tloaelo tsa peptide, ho kenyelletsa CRO, CMO, le litharollo tsa OEM,Peptide-drug conjugates (PDCs), ho kenyelletsa peptide-radionuclide, molek'hule e nyane ea peptide, protheine ea peptide, le peptide-RNA therapeutics..

LIHLAHISO TSE KHOLO

Bakeng sa lintlha tse ling ka lihlahisoa tsa rona, ka kopo ikopanye le rona.

Lipotso tsa Global API le Cosmetic: Tel No.: +86-15013529272;

Ngoliso ea API & Litšebeletso tsa CDMO (Mmaraka oa USA EU）: +86-15818682250

E-mail:jymed@jymedtech.com

Aterese: Floors 8 & 9, Building 1, Shenzhen Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi Subtistrict, Pingshan District, Shenzhen